Sunnyvale, Calif. April 8, 2005 - Molecular Devices Corporation (NASDAQ: MDCC) today announced the introduction of two new reagent products for ADME assay screening-Transil® Membrane Affinity and Transil Human Serum Albumin (HSA) Binding assay kits. The Transil assay kits provide lead optimization and high-throughput screening laboratories with fast, automatable, direct, biologically relevant solutions to increase the throughput of ADME-related compound profiling.
The Transil Membrane Affinity assay provides data that correlates better to in vivo studies compared to the more conventional water/octanol partitioning assays because it uses beads which are coated with a lipid bilayer that mimic interactions between compounds and cell membranes. The results are equivalent to the liposome "gold standard" method, without the tedious preparation of liposomes.
The Transil HSA Binding assay kit makes routine, high-throughput HSA binding characterization easy because it contains beads which have been coated with human serum albumin and pre-dispensed into a microplate format. The pre-dispensed format increases throughput via parallel sample preparation and assay reading on Molecular Devices' SpectraMax® microplate readers.
With the Transil assays, there is virtually no methods development required, as each kit contains data analysis routines for processing high-throughput screening of drug candidates for early ADME characterization. Furthermore, the assays share nearly identical sample workup steps, so steps developed for one assay are immediately applicable to the other.
Commenting on the launch, Christopher Silva, Director of Marketing for Life Sciences Products at Molecular Devices stated, "The Transil assay kits enable screening of compound libraries for membrane affinity and HSA binding for early ADME properties which are not possible with current low-throughput methods. These new assays require only one sample concentration, which simplifies automation. Additionally, turnkey data analysis offers researchers compound data within hours of synthesis or secondary screening. Because we have integrated these assays with our SpectraMax® microplate reader line, we have provided a more complete solution to our customers."
The kits are available in two formats for 96- or 384-well microplates. The "high precision" version is ideal for profiling compounds at the lead optimization stage of drug discovery; the "high throughput" version allows characterization of compound libraries.